Xiaohong Liang1, Qing Li2, Bin Xu3, Song Hu1, Qianyun Wang4, Yan Li1, Yun Zong1, Sujuan Zhang1, Chong Li5. 1. Department of Respiratory Medicine, The Third Affiliated Hospital of Soochow University, No.185, Juqian Road, Tianning District, Changzhou City, Jiangsu Province, People's Republic of China. 2. Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People's Republic of China. 3. Cancer Center, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People's Republic of China. 4. Department of Thoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People's Republic of China. 5. Department of Respiratory Medicine, The Third Affiliated Hospital of Soochow University, No.185, Juqian Road, Tianning District, Changzhou City, Jiangsu Province, People's Republic of China. zeyou06@163.com.
Abstract
INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a group of rare tumors with the presence of both cancerous and sarcoma components in tumor. In this study, we explore their cancer genomic background and the relationship with clinical prognosis. MATERIALS AND METHODS: A cohort of 32 PSC patients were retrospectively collected from the First People's Hospital of Changzhou between 2005 and 2016. Targeted next-generation sequencing (NGS) of 416 cancer-relevant genes was performed on 32 PSC tumors. RESULTS: EGFR (28%), KRAS (22%), and MET (16%) are the most commonly mutated oncogenes, while the top mutated tumor suppressor genes are TP53 (69%) and RB1 (25%). The majority of EGFR mutations are rare mutations, some of which have not been reported before. Moreover, 4 out of 6 MET alterations are exon 14 skipping, far more frequent than in NSCLC. Interestingly, ARID1A was found to be co-mutated with TP53 at all times. The tumor mutation burden (TMB) is ranging from 3.3 to 52.2 per megabase (MB) with a median of 11.7 per MB and 13 patients have more than 20 mutations per MB. Patients mutated in BRCA2, KMT2B, SMARCA4 or TSC2 have significantly higher TMB compared to patients with wide-type genes. CONCLUSION: Our study characterizes the genetic background of Chinese PSC patients and demonstrates the importance of involving EGFR rare mutations and MET exon 14 skipping targeted therapies into clinical trials for treating PSC patients. High TMB are seen in about 40.6% Chinese patients with PSC, which could benefit from immune checkpoint inhibitors.
INTRODUCTION:Pulmonary sarcomatoid carcinoma (PSC) is a group of rare tumors with the presence of both cancerous and sarcoma components in tumor. In this study, we explore their cancer genomic background and the relationship with clinical prognosis. MATERIALS AND METHODS: A cohort of 32 PSC patients were retrospectively collected from the First People's Hospital of Changzhou between 2005 and 2016. Targeted next-generation sequencing (NGS) of 416 cancer-relevant genes was performed on 32 PSC tumors. RESULTS:EGFR (28%), KRAS (22%), and MET (16%) are the most commonly mutated oncogenes, while the top mutated tumor suppressor genes are TP53 (69%) and RB1 (25%). The majority of EGFR mutations are rare mutations, some of which have not been reported before. Moreover, 4 out of 6 MET alterations are exon 14 skipping, far more frequent than in NSCLC. Interestingly, ARID1A was found to be co-mutated with TP53 at all times. The tumor mutation burden (TMB) is ranging from 3.3 to 52.2 per megabase (MB) with a median of 11.7 per MB and 13 patients have more than 20 mutations per MB. Patients mutated in BRCA2, KMT2B, SMARCA4 or TSC2 have significantly higher TMB compared to patients with wide-type genes. CONCLUSION: Our study characterizes the genetic background of Chinese PSC patients and demonstrates the importance of involving EGFR rare mutations and MET exon 14 skipping targeted therapies into clinical trials for treating PSC patients. High TMB are seen in about 40.6% Chinese patients with PSC, which could benefit from immune checkpoint inhibitors.
Authors: Sai Yendamuri; Laura Caty; Marybeth Pine; Soumya Adem; Paul Bogner; Austin Miller; Todd L Demmy; Adrienne Groman; Mary Reid Journal: Surgery Date: 2012-06-26 Impact factor: 3.982
Authors: Oluwole Fadare; Katja Gwin; Mohamed M Desouki; Marta A Crispens; Howard W Jones; Dineo Khabele; Sharon X Liang; Wenxin Zheng; Khaled Mohammed; Jonathan L Hecht; Vinita Parkash Journal: Mod Pathol Date: 2013-03-22 Impact factor: 7.842
Authors: Myung-Ju Ahn; Byeong-Bae Park; Jin Seok Ahn; Sang We Kim; Heung-Tae Kim; Jong Seog Lee; Jin Hyung Kang; Jae Yong Cho; Hong Suk Song; Se Hoon Park; Chang Hak Sohn; Sang Won Shin; Jin Hyuck Choi; Chang-Seok Ki; Chan Keum Park; Alison J Holmes; Pasi A Jänne; Keunchil Park Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz Journal: Nature Date: 2013-06-16 Impact factor: 49.962